Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) was downgraded by stock analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research note issued on Monday.
EYPT has been the subject of a number of other reports. Royal Bank Of Canada cut their target price on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Stifel Nicolaus began coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price objective for the company. Chardan Capital restated a “buy” rating and set a $65.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Monday. Guggenheim reaffirmed a “buy” rating and set a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Finally, HC Wainwright decreased their target price on shares of Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eyepoint Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $44.38.
Get Our Latest Stock Analysis on Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals Price Performance
Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The company had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. As a group, sell-side analysts forecast that Eyepoint Pharmaceuticals will post -3.6 EPS for the current year.
Institutional Investors Weigh In On Eyepoint Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its holdings in shares of Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the period. RWC Asset Management LLP increased its position in shares of Eyepoint Pharmaceuticals by 6.4% during the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after purchasing an additional 1,040 shares during the last quarter. MCF Advisors LLC raised its holdings in Eyepoint Pharmaceuticals by 8.3% in the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock valued at $273,000 after buying an additional 1,149 shares during the period. Raymond James Financial Inc. lifted its position in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after buying an additional 1,177 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after buying an additional 1,358 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.
Eyepoint Pharmaceuticals Company Profile
Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.
Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.
Featured Articles
- Five stocks we like better than Eyepoint Pharmaceuticals
- These 5 Dividend Stocks Show Why Income Investing Still Matters
- The Quantum Race Is Heating Up—And 2 Small Players Stand Out
- 3 Robotics Stocks Under $10: Value, Momentum, or Bet?
- 3 ETFs Built to Protect Your Money if the Bull Market Breaks
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
